A controversial hepatitis B vaccine trial planned for Guinea-Bissau is now "on full hold," the dean of the University of Southern Denmark told BioXconomy. The decision comes following news of irregularities and undisclosed conflicts of interest in the local ethical approval process.
March 17, 2026 at 7:51 AM
A controversial hepatitis B vaccine trial planned for Guinea-Bissau is now "on full hold," the dean of the University of Southern Denmark told BioXconomy. The decision comes following news of irregularities and undisclosed conflicts of interest in the local ethical approval process.
I spoke with journalist Søren Hough at BioXconomy about RFK Jr & Jay Bhattacharya's pathetic, anti-scientific, fact-free reasons they gave for canceling mRNA vaccine R&D.
"Perhaps we should not have been surprised," I said, "given their anti-vaccine activism.”
www.bioxconomy.com/modalities/e...
"Perhaps we should not have been surprised," I said, "given their anti-vaccine activism.”
www.bioxconomy.com/modalities/e...
Experts reject HHS disparagement of mRNA technology
World-leading vaccine and public health experts say NIH director Jay Bhattacharya’s recent op-ed is “infuriating” and “anti-scientific.”
www.bioxconomy.com
August 28, 2025 at 3:27 PM
I spoke with journalist Søren Hough at BioXconomy about RFK Jr & Jay Bhattacharya's pathetic, anti-scientific, fact-free reasons they gave for canceling mRNA vaccine R&D.
"Perhaps we should not have been surprised," I said, "given their anti-vaccine activism.”
www.bioxconomy.com/modalities/e...
"Perhaps we should not have been surprised," I said, "given their anti-vaccine activism.”
www.bioxconomy.com/modalities/e...
BREAKING: The Health Research Ethics Committee for the Region of Southern Denmark has responded to BioXconomy to acknowledge that it is investigating whether this trial met notification requirements. The article has been updated to reflect this point.
February 18, 2026 at 11:53 AM
BREAKING: The Health Research Ethics Committee for the Region of Southern Denmark has responded to BioXconomy to acknowledge that it is investigating whether this trial met notification requirements. The article has been updated to reflect this point.
Stabell Benn: "Under Danish regulations, ethics committees in Denmark do not review protocols for studies conducted entirely outside Denmark."
"That statement contradicts both the Declaration of Helsinki and the statements BioXconomy received from Danish institutions..."
Ny interessant artikel ⬇️ 👀
"That statement contradicts both the Declaration of Helsinki and the statements BioXconomy received from Danish institutions..."
Ny interessant artikel ⬇️ 👀
Hepatitis vaccine trial bucks ethics standards, says WHO
The study would mean applying a “double standard” to standards of care between the sponsoring countries – Denmark and the US – and the host country.
www.bioxconomy.com
February 18, 2026 at 10:46 AM
Stabell Benn: "Under Danish regulations, ethics committees in Denmark do not review protocols for studies conducted entirely outside Denmark."
"That statement contradicts both the Declaration of Helsinki and the statements BioXconomy received from Danish institutions..."
Ny interessant artikel ⬇️ 👀
"That statement contradicts both the Declaration of Helsinki and the statements BioXconomy received from Danish institutions..."
Ny interessant artikel ⬇️ 👀
I don't want to spoil her incredible story. I promise it's better if you hear it from her.
Check the comments below for a link to the episode and full transcript over at BioXconomy.
Check the comments below for a link to the episode and full transcript over at BioXconomy.
September 23, 2026 at 2:57 PM
I don't want to spoil her incredible story. I promise it's better if you hear it from her.
Check the comments below for a link to the episode and full transcript over at BioXconomy.
Check the comments below for a link to the episode and full transcript over at BioXconomy.
Experimental DIY peptides are taking the US by storm. BioXconomy and BPI investigate the booming underground peptide market - and the dangers it brings with it.
Read my full investigative piece below:
#peptide #glp #investigation
www.bioxconomy.com/modalities/d...
Read my full investigative piece below:
#peptide #glp #investigation
www.bioxconomy.com/modalities/d...
Experimental injectable peptides craze takes US by storm
BioXconomy and BPI investigate the booming underground peptide market – and the dangers it brings with it.
www.bioxconomy.com
May 12, 2026 at 4:02 PM
Experimental DIY peptides are taking the US by storm. BioXconomy and BPI investigate the booming underground peptide market - and the dangers it brings with it.
Read my full investigative piece below:
#peptide #glp #investigation
www.bioxconomy.com/modalities/d...
Read my full investigative piece below:
#peptide #glp #investigation
www.bioxconomy.com/modalities/d...
Industry news of the day · 18.02.26
Understand partnering in China by understanding the journey - BioXconomy
Understand partnering in China by understanding the journey BioXconomy
Subnewsletter
#ProteinDesign #StructuralBiology #Bioinformatics #ProteinEngineering
Understand partnering in China by understanding the journey - BioXconomy
Understand partnering in China by understanding the journey BioXconomy
Subnewsletter
#ProteinDesign #StructuralBiology #Bioinformatics #ProteinEngineering
Understand partnering in China by understanding the journey - BioXconomy
Understand partnering in China by understanding the journey BioXconomy
news.google.com
February 18, 2026 at 9:00 AM
Industry news of the day · 18.02.26
Understand partnering in China by understanding the journey - BioXconomy
Understand partnering in China by understanding the journey BioXconomy
Subnewsletter
#ProteinDesign #StructuralBiology #Bioinformatics #ProteinEngineering
Understand partnering in China by understanding the journey - BioXconomy
Understand partnering in China by understanding the journey BioXconomy
Subnewsletter
#ProteinDesign #StructuralBiology #Bioinformatics #ProteinEngineering
Thanks as ever to Joshua Abbott for partnering with me in this ongoing investigation. Our full story at BioXconomy, no paywall: www.bioxconomy.com/modalities/g...
Hepatitis vaccine trial bucks ethics standards, says WHO
The study would mean applying a “double standard” to standards of care between the sponsoring countries – Denmark and the US – and the host country.
www.bioxconomy.com
February 18, 2026 at 8:51 AM
Thanks as ever to Joshua Abbott for partnering with me in this ongoing investigation. Our full story at BioXconomy, no paywall: www.bioxconomy.com/modalities/g...
A good first post might be the link to this new "about us" interview in BioXconomy. www.bioxconomy.com/innovation/n...
Nonprofit looks to bring tomorrow’s science into today’s classrooms
BioXconomy sat down with Natalie Kuldell, founder and executive director of nonprofit organization BioBuilder Education Foundation, to discuss its function, its importance, and its effect in the life ...
www.bioxconomy.com
November 20, 2024 at 3:51 PM
A good first post might be the link to this new "about us" interview in BioXconomy. www.bioxconomy.com/innovation/n...
I am so proud of the work our BioXconomy Modalities team — in particular, Nnenna Ohaka and Millie Hoe — did over the course of 2025. The article below is only a small sampling.
Below, you’ll find entries from Drug Modalities Editor Søren Hough (SH) and reporters Nnenna Ohaka (NO) and Millie Hoe (MH) as they reflect on some of their favorite news stories of the year.
Read the full article below:
www.bioxconomy.com/modalities/y...
Read the full article below:
www.bioxconomy.com/modalities/y...
The BioXconomy Modalities team’s favorite innovations of 2025
Reflecting on a year of landmark therapeutic discoveries in cancer research, infectious disease, and more.
www.bioxconomy.com
January 6, 2026 at 1:11 PM
I am so proud of the work our BioXconomy Modalities team — in particular, Nnenna Ohaka and Millie Hoe — did over the course of 2025. The article below is only a small sampling.
11/12
"HHS told BioXconomy that the trial is merely paused for the time being.The agency anticipates it will go ahead once it has undergone evaluation.
As the trial's parameters currently stand, Yamey emphasized a bleak reality..
"HHS told BioXconomy that the trial is merely paused for the time being.The agency anticipates it will go ahead once it has undergone evaluation.
As the trial's parameters currently stand, Yamey emphasized a bleak reality..
January 28, 2026 at 10:36 AM
11/12
"HHS told BioXconomy that the trial is merely paused for the time being.The agency anticipates it will go ahead once it has undergone evaluation.
As the trial's parameters currently stand, Yamey emphasized a bleak reality..
"HHS told BioXconomy that the trial is merely paused for the time being.The agency anticipates it will go ahead once it has undergone evaluation.
As the trial's parameters currently stand, Yamey emphasized a bleak reality..
Preclinical research shows ASOs could delay retinal degeneration in juvenile Batten’s disease.
BioXconomy spoke to study author Michelle Hastings about what her team’s findings could mean for the future treatment of Batten disease.
Read my full article below:
www.bioxconomy.com/modalities/a...
BioXconomy spoke to study author Michelle Hastings about what her team’s findings could mean for the future treatment of Batten disease.
Read my full article below:
www.bioxconomy.com/modalities/a...
ASOs could delay blindness in children with Batten's
Preclinical research shows ASOs could delay retinal degeneration in juvenile Batten’s disease.
www.bioxconomy.com
November 27, 2025 at 3:02 PM
Preclinical research shows ASOs could delay retinal degeneration in juvenile Batten’s disease.
BioXconomy spoke to study author Michelle Hastings about what her team’s findings could mean for the future treatment of Batten disease.
Read my full article below:
www.bioxconomy.com/modalities/a...
BioXconomy spoke to study author Michelle Hastings about what her team’s findings could mean for the future treatment of Batten disease.
Read my full article below:
www.bioxconomy.com/modalities/a...
Below, you’ll find entries from Drug Modalities Editor Søren Hough (SH) and reporters Nnenna Ohaka (NO) and Millie Hoe (MH) as they reflect on some of their favorite news stories of the year.
Read the full article below:
www.bioxconomy.com/modalities/y...
Read the full article below:
www.bioxconomy.com/modalities/y...
The BioXconomy Modalities team’s favorite innovations of 2025
Reflecting on a year of landmark therapeutic discoveries in cancer research, infectious disease, and more.
www.bioxconomy.com
January 6, 2026 at 10:24 AM
Below, you’ll find entries from Drug Modalities Editor Søren Hough (SH) and reporters Nnenna Ohaka (NO) and Millie Hoe (MH) as they reflect on some of their favorite news stories of the year.
Read the full article below:
www.bioxconomy.com/modalities/y...
Read the full article below:
www.bioxconomy.com/modalities/y...
In a world first, a progressive multiple sclerosis patient at Nebraska Medicine was treated with an allogeneic CAR T therapy.
“I'm walking. My gait is so much better,” she said. “I feel better.”
You can read my full article over at BioXconomy: www.bioxconomy.com/modalities/m...
#CellTherapy
“I'm walking. My gait is so much better,” she said. “I feel better.”
You can read my full article over at BioXconomy: www.bioxconomy.com/modalities/m...
#CellTherapy
Multiple sclerosis patient treated with CAR T therapy
A landmark allogeneic cell therapy treatment could alter the futures of MS patients facing progressive neurodegeneration.
www.bioxconomy.com
September 5, 2025 at 5:32 PM
In a world first, a progressive multiple sclerosis patient at Nebraska Medicine was treated with an allogeneic CAR T therapy.
“I'm walking. My gait is so much better,” she said. “I feel better.”
You can read my full article over at BioXconomy: www.bioxconomy.com/modalities/m...
#CellTherapy
“I'm walking. My gait is so much better,” she said. “I feel better.”
You can read my full article over at BioXconomy: www.bioxconomy.com/modalities/m...
#CellTherapy
Now that we're on a shiny new website over at BioXconomy, I figured I'd reshare some of my favorite articles I've written.
First up, my editorial about how CRISPR was both essential to my PhD research and also has the potential to fuel a new eugenics movement:
www.bioxconomy.com/modalities/f...
First up, my editorial about how CRISPR was both essential to my PhD research and also has the potential to fuel a new eugenics movement:
www.bioxconomy.com/modalities/f...
Fixing what isn’t broken: CRISPR’s potential to erase biocultural diversity Søren Hough, PhD Søren Hough, PhD
CRISPR has accelerated healthcare research, but risks being pulled into dark history plagued by racism and ableism.
www.bioxconomy.com
August 20, 2025 at 11:29 AM
Now that we're on a shiny new website over at BioXconomy, I figured I'd reshare some of my favorite articles I've written.
First up, my editorial about how CRISPR was both essential to my PhD research and also has the potential to fuel a new eugenics movement:
www.bioxconomy.com/modalities/f...
First up, my editorial about how CRISPR was both essential to my PhD research and also has the potential to fuel a new eugenics movement:
www.bioxconomy.com/modalities/f...
This one's special, folks. I'm so excited to announce the latest episode of our BioXconomy podcast, Dose of Discovery, features a conversation with my old colleague and CRISPR legend @eriksontheimer.bsky.social.
August 27, 2026 at 11:37 AM
This one's special, folks. I'm so excited to announce the latest episode of our BioXconomy podcast, Dose of Discovery, features a conversation with my old colleague and CRISPR legend @eriksontheimer.bsky.social.
Yammer is Not Just Facebook for Enterprises: A Deep Dive with CEO David Sacks http://xconomy.com/?p=159951
BioXconomy
BioXconomy provides information and insights for life sci...
xconomy.com
November 21, 2024 at 9:59 PM
Yammer is Not Just Facebook for Enterprises: A Deep Dive with CEO David Sacks http://xconomy.com/?p=159951
Unleash the Hedgehog! Love it. Too bad they keep forgetting that it's Sonic Hh. #cancer #SMO #Shh #Hedgehog http://xconomy.com/?p=144243
BioXconomy
BioXconomy provides information and insights for life sciences investment, innovation and partnering.
xconomy.com
December 1, 2024 at 8:34 PM
Unleash the Hedgehog! Love it. Too bad they keep forgetting that it's Sonic Hh. #cancer #SMO #Shh #Hedgehog http://xconomy.com/?p=144243
🌟 Celebrating our clients’ media successes! March was a month of collaborations for ALA clients, here are our highlights:
1️⃣ Kayentis’ CMO Estelle Haenel spoke with BioXconomy about their new strategic partnership with Perceptive eClinical, tackling digital complexity in global clinical trials.
1️⃣ Kayentis’ CMO Estelle Haenel spoke with BioXconomy about their new strategic partnership with Perceptive eClinical, tackling digital complexity in global clinical trials.
April 27, 2026 at 8:15 AM
🌟 Celebrating our clients’ media successes! March was a month of collaborations for ALA clients, here are our highlights:
1️⃣ Kayentis’ CMO Estelle Haenel spoke with BioXconomy about their new strategic partnership with Perceptive eClinical, tackling digital complexity in global clinical trials.
1️⃣ Kayentis’ CMO Estelle Haenel spoke with BioXconomy about their new strategic partnership with Perceptive eClinical, tackling digital complexity in global clinical trials.
Check out my piece at BioXconomy for more: www.bioxconomy.com/modalities/p...
Peptide conjugates loosen up antibody therapeutics
Antibody-peptide conjugates could enable parallel pathway targeting for subtler disease treatments.
www.bioxconomy.com
March 25, 2026 at 1:41 PM
Check out my piece at BioXconomy for more: www.bioxconomy.com/modalities/p...
Check out our full story at BioXconomy: www.bioxconomy.com/modalities/b...
A vaccine trial in Guinea-Bissau comes under intense scrutiny
An RFK, Jr.-linked vaccine trial in Guinea-Bissau is not cancelled, despite reports.
www.bioxconomy.com
January 28, 2026 at 1:32 PM
Check out our full story at BioXconomy: www.bioxconomy.com/modalities/b...
My full article over at BioXconomy: www.bioxconomy.com/modalities/g...
'Cure’ for deadly pediatric condition hits milestone
A joint research initiative between UCL and UCLA has produced a gene therapy with a 95% success rate and no safety concerns in multi-year follow-up.
www.bioxconomy.com
November 1, 2025 at 12:21 PM
My full article over at BioXconomy: www.bioxconomy.com/modalities/g...
RT @Xconomy $2M Achieves Liftoff For Detroit LaunchPad http://xconomy.com/?p=76833#in Entrepreneurship is a career.
BioXconomy
BioXconomy provides information and insights for life sci...
xconomy.com
December 9, 2024 at 6:20 PM
RT @Xconomy $2M Achieves Liftoff For Detroit LaunchPad http://xconomy.com/?p=76833#in Entrepreneurship is a career.
RT @Xconomy First Impressions of Michigan’s Innovation Landscape: An Institutional Legacy, A Fragmented... http://xconomy.com/?p=108897 #in
BioXconomy
BioXconomy provides information and insights for life sci...
xconomy.com
December 9, 2024 at 1:21 PM
RT @Xconomy First Impressions of Michigan’s Innovation Landscape: An Institutional Legacy, A Fragmented... http://xconomy.com/?p=108897 #in